C-RAD AB (publ) has been approved for listing on N

The Listing Committee of the Stockholm Stock Exchange has approved C-RAD AB (publ) “C-RAD” for listing on Nasdaq Stockholm, Small Cap. The first day of trading in C-RAD's shares, Series B, on Nasdaq Stockholm is planned to be 16 December 2014.

Through this listing, the listing on Nasdaq First North Premier shall cease, and the final day of trading in the shares on First North is planned to be 15 December 2014. The company's shareholders do not need to take any action in connection with the listing. The shares will be traded under the same ticker symbol as before, CRAD B. The share will also keep the same ISIN code as before, i.e. SE0002016352. There will be no new issue of shares in connection with the listing.

“The decision to list the share on Nasdaq Stockholm is a natural next step for C-RAD,” says Tim Thurn, CEO of C-RAD. “We have great hopes of attracting major investors and institutions. A majority of larger funds and institutions may only invest in companies whose shares are traded on a regulated market. Moreover, we expect to receive increased attention from foreign investors. In 2014, C-RAD is expected to generate approximately 75 percent of its total sales outside Sweden. C‑RAD's focus is to show continued growth and expand the business, primarily within patient positioning. The organization and resources required to ensure continued expansion have been implemented.”

C-RAD hereby publishes the prospectus that was prepared in connection with the listing, and which has been approved by the Swedish Financial Supervisory Authority. The prospectus will be available from today on the Company's website, www.c-rad-se, and on www.penser.se.

Erik Penser Bankaktiebolag is the financial adviser and Baker & McKenzie Advokatbyrå KB is the legal adviser in relation to the listing.

Uppsala, December 12, 2014

C-RAD AB (publ)

The Board of Directors

About C-RAD

C-RAD develops innovative solutions for use in advanced radiation therapy. The C-RAD group offers products and solutions for patient positioning, tumor localization and radiation treatment systems. End users are radiation therapy clinics worldwide. All product development is conducted in three fully owned subsidiaries: C-RAD Positioning AB, C-RAD Imaging AB and C-RAD Innovation AB, all of which are located in Uppsala, Sweden. Employees currently number 28. C-RAD’s business originates from research and development at Karolinska Institutet in Solna, Sweden. Sales of the company’s first product, the C-RAD Sentinel ^TM , started in 2007. Cooperation agreements have been signed with Elekta (Sweden), Varian (USA) and IBA (Belgium). C-RAD is represented by distributors specialized in radiation therapy on major markets. C-RAD has established three companies for direct sales: C-RAD Inc. in the US, C-RAD GmbH in Germany and C-RAD WOFE in China. C-RAD holds 29% of the laser company Cyrpa with an option to acquire the remaining 71%. C-RAD AB is listed – since March 2010 – on NASDAQ OMX First North Premier. Erik Penser Bankaktiebolag is appointed as C‑RAD’s Certified Adviser.

For more information on C-RAD, please visit www.c-rad.com .

For further information:

Tim Thurn, CEO C-RAD AB, Phone +46-18-666947, Email investors@c-rad.com

The above information is price-sensitive and must therefore be disclosed under the Securities Market Act (2077:528).